Maxwell is expanding its AI-first approach with the launch of a formal AI division focused on accelerating drug discovery and the development of AI-powered medical devices. As part of this initiative, Jon McClure has been named CTO to lead the company’s AI engineering strategy. “The future of medicine requires scalable intelligence, and Jon brings exactly that—combined with deeply human values,” said CEO, Founder & Chairman Joshua McClure. “Our AI division will serve as both accelerator and amplifier—driving faster drug design, analyzing clinical trial data and infusing every part of Maxwell with AI.” AI has been central to Maxwell’s work since its founding in 2016—designing molecules, modeling biology and streamlining operations in real time. This new division deepens that commitment, supporting scalable innovation across all areas of the business. 📍 Read the full announcement: https://lnkd.in/eCY5mG3D #MaxwellBiosciences #AI #DrugDiscovery #HealthTech #Claromers #CTO #BiotechLeadership #AIDivision
Maxwell Biosciences
Biotechnology Research
Austin, Texas 1,452 followers
Next Generation Anti-Infectives: A drug platform confirmed by independent labs to destroy all tested pathogenic microbes
About us
Next Generation Anti-Infectives that Mimic Natural Human Antimicrobial Peptides Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented low molecular weight drug candidates that destroy SARS-CoV-2, the COVID virus, as well as other viruses and infectious pathogens (including fungal and bacterial pathogens). Maxwell's first-in-class CLAROMER™ brand drug discovery platform mimics natural human immune system antimicrobial and antiviral peptides. Maxwell Biosciences has benefitted from over $35M of non-dilutive grants and awards from governments around the world to validate their science and technology, including studies by US Govt-funded labs confirming that Maxwell's lead drug candidate has direct virucidal action against Herpes virus (HSV-1) and SARS-CoV-2, the COVID virus. Additionally, live mouse safety data at Texas A&M show Maxwell's drugs benefit from a tissue-safe toxicology profiles, and live mouse studies from the Baylor College of Medicine show breakthrough fungicidal action with CLAROMER™ brand compounds against lethal fungal infections of the upper-respiratory tract. These findings support the expected safety and effectiveness of Maxwell's “multi-asset, multi-target” anti-infectives drug platform. Maxwell's drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics and a broad spectrum of evolving infectious pathogens. Maxwell is raising funds for advanced preclinical and human trials.
- Website
-
https://maxwellbiosciences.com/
External link for Maxwell Biosciences
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Austin, Texas
- Type
- Privately Held
- Founded
- 2016
Locations
-
Primary
Get directions
Austin, Texas, US
Employees at Maxwell Biosciences
-
Beth Burnside, Ph.D.
Sr. Vice President Research & Development Strategy
-
Jon McClure
Chief Technology Officer at Maxwell Biosciences
-
Joshua McClure
CEO @ Maxwell Biosciences - developing broad spectrum biodefense designed to extend healthspan by destroying viruses, fungi and bacteria with a…
-
Sarah Aubrey
Investor Relations; Complex & Strategic Project Planning
Updates
-
Join Maxwell Biosciences at Aging Research & Drug Discovery Meeting 2025—the premier global meeting for aging research and drug discovery. Our COO & Head of R&D Edward M. Rudnic, Ph.D. will present a keynote entitled: “Longevity Peptides, the Microbiome and the Gut-Brain Axis” This session will explore how immune-inspired peptide mimics may unlock new interventions at the intersection of microbial health, neurological function and longevity. For leaders in peptide innovation, neurobiology or microbiome science—this is one to watch. #Longevity #AgingResearch #GutBrainAxis #Microbiome #MaxwellBiosciences #ARDD2025 #DrugDiscovery #TranslationalScience August 25–29 | University of Copenhagen & Virtual Learn more at https://agingpharma.org
-
📢 Reminder: Join us at the 12th Annual Aging Research & Drug Discovery Meeting (ARDD 2025) from August 25-29 at the University of Copenhagen’s Ceremonial Hall or online. Our COO and Head of R&D, Edward M. Rudnic, Ph.D. will be speaking at this premier longevity conference, alongside global leaders like Nobel laureates Morten Meldal and Michael Levitt. Don’t miss the latest advancements in aging research and drug discovery. Secure your spot for virtual or in-person attendance at agingpharma.org. #ARDD2025 #AgingResearch #Longevity #MaxwellBiosciences
-
Today, Maxwell Biosciences announces strategic partnerships and licensing in cosmetics and personal care with our immune-inspired Claromer™ platform. Claromers™ are immune-inspired molecules designed to support the skin microbiome while providing broad-spectrum protection. -- Engineered for stability and safety -- Effective against bacteria, fungi, viruses and biofilms -- Compatible with the needs of modern skincare innovators We’re enabling a new era of microbiome-safe, science-backed personal care. 📣 Learn more and watch our announcement video: 🔗 https://lnkd.in/eb4TcjUZ #CosmeticsInnovation #MicrobiomeSafe #Licensing #Claromers #MaxwellBiosciences
-
-
Thanks for the shoutout, The Defense Post!
🧑🔬👏 The US Navy has signed an agreement with Maxwell Biosciences to conduct in vitro testing of a peptide drug to decrease diarrhea in warfighters. The research will focus on the illness’ treatment and prevention using the company’s proprietary Claromers solution, which consists of synthetic oligomer molecules that mimic the human body’s “primary line of innate immune defense against rapidly evolving viruses.” Founder and CEO Joshua McClure highlighted the significance of the Claromers trials for the health of the nation’s fighters. “This partnership isn’t just about stopping pathogens; it’s about keeping our forces mission-ready and preventing critical situations from going down the drain,” McClure said.
-
-
Diarrheal disease remains the #1 infectious threat to U.S. troop readiness. Drug-resistant pathogens are outpacing conventional antibiotics, threatening both mission performance and long-term health. Today, we’re proud to announce a new Limited Purpose Cooperative Research and Development Agreement (LP-CRADA) with the U.S. Naval Medical Research Command’s DAID lab to evaluate our Claromer™ compounds as a next-generation solution. Here's the highlights: 🔹 7th U.S. military collaboration 🔹 Claromers™ = synthetic small molecules mimicking innate immune system 🔹 Broad-spectrum efficacy against bacteria, viruses, fungi and biofilms 🔹 Stable, scalable and engineered for extreme environments This partnership further validates Claromers™ as a mission-ready innovation uniquely positioned to defend against one of the military’s most pervasive threats. 📍 Learn more at: https://lnkd.in/eQ3JtMk7 #DefenseInnovation #BiotechLeadership #CombatReadiness #AntimicrobialResistance #DrugDiscovery #MaxwellBiosciences #OneDrugManyBugs #MilitaryHealth
-
Discover how Maxwell Biosciences is advancing biodefense with its Claromer™ platform in an exclusive Contract Pharma interview. CEO Joshua McClure discusses U.S. Military partnerships, a $3M MTEC award and innovative therapeutics for infectious diseases like Dengue Fever. Read the full story to explore Maxwell's vision for global health security: https://lnkd.in/egAyNsDE
-
-
ICYMI: Maxwell Biosciences CEO on Claromers™ and the Future of Longevity In a recent Lifespan.io Longevity News interview, Maxwell CEO Joshua McClure dives into how Claromers™—synthetic small molecules mimicking the immune peptide LL-37—could transform healthspan by combating infectious disease. From nonhuman primate trials to collaborations with the US military and India, McClure outlines a bold vision: eradicating infections as the primary driver of aging. Read the full interview here: https://lnkd.in/e8GJr-yA
-
Maxwell Biosciences announces that Edward M. Rudnic, Ph.D., our COO and Head of R&D, will speak at the 12th Annual Aging Research & Drug Discovery Meeting (ARDD 2025), the preeminent conference in aging research and longevity. Hosted by the University of Copenhagen, ARDD 2025 runs August 25-29 at the Ceremonial Hall and will also be streaming online. The 2025 program brings together global authorities in longevity, including Nobel laureates Morten Meldal and Michael Levitt, to address advancements in aging science and drug discovery. Join us—tickets are available for virtual or in-person attendance. Register at agingpharma.org. #ARDD2025 #AgingResearch #Longevity
-
-
Maxwell Biosciences is pleased to sponsor the 12th Aging Research & Drug Discovery Meeting (#ARDD2025), the preeminent event in aging research and longevity technology. This year’s meeting runs August 25-29, 2025 at the University of Copenhagen's Ceremonial Hall. The event will also stream online. According the United Nations, people over 65 now outnumber children under 5—a shift driving new challenges and opportunities in age-related disease research. At #ARDD2025, global thought-leaders, including Nobel laureates Morten Meldal and Michael Levitt, will share groundbreaking insights on targeting the aging process to improve healthspan. This is the world’s largest conference of its kind, bringing together academic luminaries, biotech innovators, and pharma leaders from companies like Novartis and Eli Lilly. We hope you’ll join us—virtual and in-person tickets are available. Register now at agingpharma.org. #ARDD2025 #AgingResearch #Longevity